MA40721A - Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation - Google Patents

Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Info

Publication number: MA40721A
Authority: MA; Morocco
Prior art keywords: interleukin; methods; fusion proteins; alpha receptor; receptor
Prior art date: 2014-08-06

Application number

MA040721A

Other languages

English (en)

Other versions

MA40721B1 (fr

Inventor

Thomas Malek

Original Assignee

The Univ Of Miami

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-06

Filing date

2015-08-05

Publication date

2017-06-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40721(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-08-05 Application filed by The Univ Of Miami filed Critical The Univ Of Miami

2017-06-13 Publication of MA40721A publication Critical patent/MA40721A/fr

2024-08-30 Publication of MA40721B1 publication Critical patent/MA40721B1/fr

Links

102000000588 Interleukin-2 Human genes 0.000 title 2
108010002350 Interleukin-2 Proteins 0.000 title 2
102000037865 fusion proteins Human genes 0.000 title 1
108020001507 fusion proteins Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Cell Biology (AREA)
Neurology (AREA)
Virology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)

MA40721A 2014-08-06 2015-08-05 Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation MA40721B1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462033726P	2014-08-06	2014-08-06
EP15750560.3A EP3177307B1 (fr)	2014-08-06	2015-08-05	Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
PCT/US2015/043792 WO2016022671A1 (fr)	2014-08-06	2015-08-05	Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Publications (2)

Publication Number	Publication Date
MA40721A true MA40721A (fr)	2017-06-13
MA40721B1 MA40721B1 (fr)	2024-08-30

Family

ID=53836871

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA40094A MA40094B1 (fr)	2014-08-06	2015-08-04	Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
MA40721A MA40721B1 (fr)	2014-08-06	2015-08-05	Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA40094A MA40094B1 (fr)	2014-08-06	2015-08-04	Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Country Status (32)

Country	Link
US (3)	US12084483B2 (fr)
EP (2)	EP3177307B1 (fr)
JP (3)	JP6723982B2 (fr)
KR (1)	KR102653758B1 (fr)
CN (2)	CN113912737A (fr)
AU (3)	AU2015301071C1 (fr)
BR (1)	BR112017001940A2 (fr)
CA (1)	CA2957273C (fr)
CL (1)	CL2017000284A1 (fr)
CO (1)	CO2017002166A2 (fr)
DK (1)	DK3177307T3 (fr)
EA (2)	EA202091342A3 (fr)
ES (1)	ES2986097T3 (fr)
FI (1)	FI3177307T3 (fr)
HR (1)	HRP20241258T1 (fr)
HU (1)	HUE068478T2 (fr)
IL (2)	IL250007B (fr)
LT (1)	LT3177307T (fr)
MA (2)	MA40094B1 (fr)
MX (1)	MX388977B (fr)
MY (1)	MY180831A (fr)
PE (1)	PE20170503A1 (fr)
PH (1)	PH12017500042A1 (fr)
PT (1)	PT3177307T (fr)
RS (1)	RS65930B1 (fr)
SA (1)	SA517380842B1 (fr)
SG (2)	SG11201700706WA (fr)
SI (1)	SI3177307T1 (fr)
SM (1)	SMT202400414T1 (fr)
TN (1)	TN2017000020A1 (fr)
WO (1)	WO2016022671A1 (fr)
ZA (1)	ZA201700245B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140044675A1 (en)	2012-08-10	2014-02-13	Roche Glycart Ag	Interleukin-2 fusion proteins and uses thereof
RS58149B1 (sr)	2014-02-06	2019-02-28	Hoffmann La Roche	Fuzioni proteini interleukina-2 i njihova upotreba
MA40094B1 (fr)	2014-08-06	2022-05-31	Univ Miami	Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP3458485B1 (fr) *	2016-05-19	2021-12-29	The General Hospital Corporation	Interleukine-2 liée à son récepteur il-2rbêta, plate-forme pour améliorer l'activité des cellules tueuses naturelles et des lymphocytes t régulateurs
CN110087681A (zh)	2016-09-28	2019-08-02	佐马美国有限公司	结合白细胞介素-2的抗体和其用途
JP7165717B2 (ja)	2017-03-15	2022-11-04	パンディオン・オペレーションズ・インコーポレイテッド	標的免疫寛容
AU2018273914A1 (en)	2017-05-24	2019-11-14	Pandion Operations, Inc.	Targeted immunotolerance
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
USRE50550E1 (en)	2017-12-06	2025-08-26	Pandion Operations, Inc.	IL-2 muteins and uses thereof
EP3746103A4 (fr) *	2017-12-06	2022-03-30	The Board of Trustees of the Leland Stanford Junior University	Protéines modifiées pour améliorer la sensibilité d'une cellule à l'il-2
US10174091B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
EP3768700A1 (fr) *	2018-03-23	2021-01-27	Kite Pharma, Inc.	Protéines transmembranaires chimériques et leurs utilisations
KR102824112B1 (ko) *	2018-03-28	2025-06-24	브리스톨-마이어스 스큅 컴퍼니	인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법
AU2020242254B2 (en)	2019-03-18	2026-03-12	Biontech Cell & Gene Therapies Gmbh	Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
CN111944036B (zh)	2019-05-14	2024-09-06	上海盖浦生物科技有限公司	一种增殖免疫细胞的突变体蛋白
CA3141327A1 (fr)	2019-05-20	2020-11-26	Pandion Operations, Inc.	Immunotolerance ciblee madcam
JP2022533254A (ja) *	2019-05-24	2022-07-21	プロヴィヴァセラピューティクス（ホンコン）リミテッド	Ｉｌ－２組成物およびその使用方法
US11246906B2 (en) *	2019-06-11	2022-02-15	Alkermes Pharma Ireland Limited	Compositions and methods for subcutaneous administration of cancer immunotherapy
AU2020315282B2 (en) *	2019-07-12	2026-02-12	Proviva Therapeutics (Hong Kong) Limited	IL-2 compositions and methods of use thereof
JP7682150B2 (ja) *	2019-07-25	2025-05-23	ザ・ユニバーシティ・オブ・シカゴ	プロテアーゼ活性化治療剤を含む組成物および方法
WO2021055568A1 (fr) *	2019-09-19	2021-03-25	Proviva Therapeutics (Hong Kong) Limited	Compositions d'il-2 et leurs procédés d'utilisation
EP4045077A1 (fr) *	2019-10-18	2022-08-24	Alkermes Pharma Ireland Limited	Agents il-2 immunolodulateurs en combinaison avec des inhibiteurs de point de contrôle immunitaire
IL293978A (en)	2019-12-20	2022-08-01	Regeneron Pharma	New il2 agonists and methods of using them
WO2021168079A1 (fr)	2020-02-21	2021-08-26	Pandion Operations, Inc.	Immunotolérance ciblée sur un tissu avec un effecteur cd39
WO2021222762A2 (fr)	2020-04-30	2021-11-04	Aetio Biotherapy, Inc.	Composition d'il2 activable et procédés d'utilisation
CN116194480A (zh) *	2020-08-13	2023-05-30	百时美施贵宝公司	将il-2重定向到目的靶细胞的方法
TW202317623A (zh) *	2021-06-14	2023-05-01	美商再生元醫藥公司	基於il2之治療劑及其使用方法
US20250032582A1 (en) *	2022-02-11	2025-01-30	Mural Oncology, Inc.	Compositions and methods for cancer immunotherapy
WO2023159135A2 (fr) *	2022-02-16	2023-08-24	University Of Miami	Protéines de fusion il-2 et tl1a et leurs procédés d'utilisation
CN114875069B (zh) *	2022-04-22	2023-09-15	四川大学	基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
JP2026508209A (ja) *	2023-02-22	2026-03-10	バイオサイトジェンファーマシューティカルズ（ベイジン）カンパニーリミテッド	抗ｉｌ２ｒａ抗体及びその使用
WO2025207491A1 (fr) *	2024-03-25	2025-10-02	Mural Oncology, Inc.	Compositions et méthodes pour immunothérapie anticancéreuse

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ201918A (en)	1981-09-18	1987-04-30	Genentech Inc	N-terminal methionyl analogues of bovine growth hormone
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en)	1987-02-17	1989-10-10	The United States Of America As Represented By The Department Of Health And Human Services	Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr)	1987-09-01	1991-05-10	Sanofi Sa	Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) *	1990-11-29	1993-10-05	Takeda Chemical Industries, Ltd.	Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
AU717779C (en)	1994-12-28	2002-12-05	University Of Kentucky	Recombinant anti-idiotype antibody 3H1 sequences relating to human carcinoembryonic antigen
US6967092B1 (en) *	1996-10-25	2005-11-22	Mc Kearn John P	Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) *	1997-01-16	1998-04-09	Hoechst Ag	Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr)	1998-05-15	2003-12-01	Bayer Ag	Agonistes et antagonistes selectifs à IL-2.
WO2003029475A1 (fr) *	2001-09-28	2003-04-10	Dnavec Research Inc.	Vecteur viral infectant une cellule de mammifere, codant pour la $g(b)2m liee a un epitope
EP1723251A4 (fr)	2004-03-05	2008-04-23	Novartis Vaccines & Diagnostic	Systeme de tests in vitro permettant de predire la tolerabilite d'agents therapeutiques chez des patients
PL1899364T5 (pl) *	2005-05-17	2024-12-09	University Of Connecticut	Kompozycje i sposoby immunomodulacji w organizmie
CN101255197B (zh)	2008-03-28	2012-01-25	浙江海正药业股份有限公司	血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) *	2008-08-21	2008-09-24	Asterion Ltd	Interleukin
EP2553101A4 (fr) *	2010-04-02	2013-09-04	Univ Rochester	Cytokines activées par des protéases
WO2012088383A2 (fr)	2010-12-23	2012-06-28	Genentech, Inc.	Interactions pilr alpha et procédés visant à les modifier
DK2859015T3 (en) *	2012-06-08	2018-06-18	Alkermes Inc	LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
US20140044675A1 (en) *	2012-08-10	2014-02-13	Roche Glycart Ag	Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (fr)	2012-12-24	2014-07-03	Beijing Anxinhuaide Biotech. Co., Ltd	Amélioration de la demi-vie d'un polypeptide thérapeutique par fusion avec une protéine d'échafaudage trimère via un espaceur
MA40094B1 (fr)	2014-08-06	2022-05-31	Univ Miami	Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

2015
- 2015-08-04 MA MA40094A patent/MA40094B1/fr unknown
- 2015-08-05 PE PE2017000128A patent/PE20170503A1/es unknown
- 2015-08-05 CN CN202110539190.4A patent/CN113912737A/zh active Pending
- 2015-08-05 PT PT157505603T patent/PT3177307T/pt unknown
- 2015-08-05 FI FIEP15750560.3T patent/FI3177307T3/fi active
- 2015-08-05 CA CA2957273A patent/CA2957273C/fr active Active
- 2015-08-05 SM SM20240414T patent/SMT202400414T1/it unknown
- 2015-08-05 US US15/501,392 patent/US12084483B2/en active Active
- 2015-08-05 ES ES15750560T patent/ES2986097T3/es active Active
- 2015-08-05 MY MYPI2017700387A patent/MY180831A/en unknown
- 2015-08-05 CN CN201580042330.XA patent/CN107074967B/zh active Active
- 2015-08-05 EP EP15750560.3A patent/EP3177307B1/fr active Active
- 2015-08-05 TN TN2017000020A patent/TN2017000020A1/en unknown
- 2015-08-05 SG SG11201700706WA patent/SG11201700706WA/en unknown
- 2015-08-05 EA EA202091342A patent/EA202091342A3/ru unknown
- 2015-08-05 EA EA201790063A patent/EA035956B1/ru not_active IP Right Cessation
- 2015-08-05 MA MA40721A patent/MA40721B1/fr unknown
- 2015-08-05 RS RS20240999A patent/RS65930B1/sr unknown
- 2015-08-05 MX MX2017001062A patent/MX388977B/es unknown
- 2015-08-05 SG SG10201913695PA patent/SG10201913695PA/en unknown
- 2015-08-05 LT LTEPPCT/US2015/043792T patent/LT3177307T/lt unknown
- 2015-08-05 JP JP2017506395A patent/JP6723982B2/ja active Active
- 2015-08-05 WO PCT/US2015/043792 patent/WO2016022671A1/fr not_active Ceased
- 2015-08-05 SI SI201532026T patent/SI3177307T1/sl unknown
- 2015-08-05 HR HRP20241258TT patent/HRP20241258T1/hr unknown
- 2015-08-05 KR KR1020177005686A patent/KR102653758B1/ko active Active
- 2015-08-05 EP EP24181690.9A patent/EP4438621A3/fr active Pending
- 2015-08-05 BR BR112017001940A patent/BR112017001940A2/pt active Search and Examination
- 2015-08-05 HU HUE15750560A patent/HUE068478T2/hu unknown
- 2015-08-05 AU AU2015301071A patent/AU2015301071C1/en active Active
- 2015-08-05 DK DK15750560.3T patent/DK3177307T3/da active
2017
- 2017-01-06 PH PH12017500042A patent/PH12017500042A1/en unknown
- 2017-01-09 IL IL250007A patent/IL250007B/en active IP Right Grant
- 2017-01-11 ZA ZA2017/00245A patent/ZA201700245B/en unknown
- 2017-02-03 CL CL2017000284A patent/CL2017000284A1/es unknown
- 2017-02-05 SA SA517380842A patent/SA517380842B1/ar unknown
- 2017-03-03 CO CONC2017/0002166A patent/CO2017002166A2/es unknown
2020
- 2020-05-22 AU AU2020203352A patent/AU2020203352B2/en active Active
- 2020-06-24 JP JP2020108721A patent/JP7272663B2/ja active Active
- 2020-07-09 IL IL275944A patent/IL275944B/en unknown
2022
- 2022-06-10 AU AU2022204034A patent/AU2022204034A1/en not_active Abandoned
- 2022-08-25 US US17/822,333 patent/US20230079120A1/en active Pending
2023
- 2023-04-20 JP JP2023069282A patent/JP2023099045A/ja active Pending
2025
- 2025-01-17 US US19/031,119 patent/US20250163118A1/en active Pending

Also Published As

Publication number	Publication date
EA201790063A1 (ru)	2017-06-30
SG11201700706WA (en)	2017-02-27
FI3177307T3 (fi)	2024-10-04
JP6723982B2 (ja)	2020-07-15
HRP20241258T1 (hr)	2024-12-06
EA035956B1 (ru)	2020-09-04
CA2957273A1 (fr)	2016-02-11
MA40094B1 (fr)	2022-05-31
JP2021000084A (ja)	2021-01-07
LT3177307T (lt)	2024-08-12
KR102653758B1 (ko)	2024-04-04
NZ766851A (en)	2024-07-26
SA517380842B1 (ar)	2021-12-26
NZ728042A (en)	2024-07-26
EA202091342A2 (ru)	2020-11-30
RS65930B1 (sr)	2024-10-31
AU2020203352A1 (en)	2020-07-02
BR112017001940A2 (pt)	2017-11-28
EP4438621A2 (fr)	2024-10-02
MY180831A (en)	2020-12-10
US20170233448A1 (en)	2017-08-17
CN107074967B (zh)	2021-06-08
ZA201700245B (en)	2024-06-26
US12084483B2 (en)	2024-09-10
TN2017000020A1 (en)	2018-07-04
IL250007B (en)	2020-07-30
PH12017500042A1 (en)	2017-05-22
EP4438621A3 (fr)	2024-12-18
EP3177307B1 (fr)	2024-07-17
IL275944A (en)	2020-08-31
SG10201913695PA (en)	2020-03-30
WO2016022671A1 (fr)	2016-02-11
MX388977B (es)	2025-03-20
EP3177307A1 (fr)	2017-06-14
AU2015301071A1 (en)	2017-02-02
AU2020203352B2 (en)	2022-03-10
CN107074967A (zh)	2017-08-18
IL275944B (en)	2022-02-01
AU2022204034A1 (en)	2022-07-14
MA40094A1 (fr)	2021-09-30
DK3177307T3 (da)	2024-10-07
US20230079120A1 (en)	2023-03-16
SMT202400414T1 (it)	2024-11-15
US20250163118A1 (en)	2025-05-22
HUE068478T2 (hu)	2025-01-28
AU2015301071C1 (en)	2020-07-02
PE20170503A1 (es)	2017-05-11
CO2017002166A2 (es)	2017-05-19
EA202091342A3 (ru)	2020-12-30
AU2015301071B2 (en)	2020-03-05
CA2957273C (fr)	2023-03-14
ES2986097T3 (es)	2024-11-08
CN113912737A (zh)	2022-01-11
MX2017001062A (es)	2017-07-14
SI3177307T1 (sl)	2024-09-30
JP7272663B2 (ja)	2023-05-12
JP2017523789A (ja)	2017-08-24
MA40721B1 (fr)	2024-08-30
KR20170030646A (ko)	2017-03-17
IL250007A0 (en)	2017-03-30
CL2017000284A1 (es)	2017-11-17
JP2023099045A (ja)	2023-07-11
PT3177307T (pt)	2024-09-13

Publication	Publication Date	Title
IL275944B (en)	2022-02-01	Fusion protein of interleukin-2 and receptor for interleukin-2 alpha and methods of use
EP3455263A4 (fr)	2020-01-01	Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
MA40921A (fr)	2017-09-12	Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
CL2016001868A1 (es)	2017-07-21	Proteinas de union y sus métodos de uso
EP3544629A4 (fr)	2020-06-17	Protéines trispécifiques ciblang le psma et procédés d'utilisation
MA43018A (fr)	2021-06-02	Anticorps anti-pd1 et procédés d'utilisation
EP3394065A4 (fr)	2019-07-10	Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
HRP20190028T1 (hr)	2019-02-22	Interleukin-2 fuzijski proteini i njihove primjene
EP3303435A4 (fr)	2019-02-20	Hydrofluoroléfines et procédés d'utilisation associés
MA44524A (fr)	2019-02-06	Néoantigènes et leurs procédés d'utilisation
EP3119761C0 (fr)	2023-06-07	Agents ciblant les amyloïdes et procédés de leur utilisation
MA47849A (fr)	2020-01-29	Anticorps anti-gitr et leurs procédés d'utilisation
MA42979A (fr)	2021-05-26	Anticorps anti-age et procédés d'utilisation correspondants
EP3394098A4 (fr)	2019-11-13	Anticorps anti-myostatine et procédés d'utilisation
EP3478277A4 (fr)	2020-01-08	Compositions anti-acné et procédés d'utilisation
EP3349851A4 (fr)	2019-04-24	Polypeptides photosensibles et leurs procédés d'utilisation
EP3365016A4 (fr)	2019-07-17	Récepteurs de cellules universels programmables et leurs procédés d'utilisation
EP3538560A4 (fr)	2020-06-17	Polypeptides de fusion gdnf et leurs procédés d'utilisation
MA40512A (fr)	2021-03-24	Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
MA45326A (fr)	2018-08-29	Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
EP2994150A4 (fr)	2016-11-16	Probiotiques et procédés d'utilisation
EP3328330A4 (fr)	2019-03-13	Manchon de cryothérapie et de compression et procédés d'utilisation
DK3158058T3 (da)	2019-07-01	Fusionsproteiner og bruger deraf
EP3322736A4 (fr)	2019-02-20	Polypeptides de fusion et leurs procédés d'utilisation
EP3630794A4 (fr)	2021-03-03	Malacidines et procédés d'utilisation